跳至主要内容
临床试验/JPRN-jRCT2080225361
JPRN-jRCT2080225361招募中3 期

Randomized phase III study of S-1 based chemotherapy plus nivolumab versus S-1 based chemotherapy alone for patients with locally advanced/borderline resectable pancreatic cancer (Investigator initiated trial)

-0 个研究点目标入组 216 人开始时间: 2020年8月25日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
-
入组人数
216

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Histologically or cytologically confirmed adenocarcinoma, adenocarcinoma squamous carcinoma of pancreatic cancer.
  • 2) Patients who confirmed unresectable locally advanced or borderline resectable pancreatic cancer
  • 3) The longest diameter of tumor does not exceed 10 cm by CT image
  • 4) No sign of direct tumor invasion into gastrointestinal tract
  • 5) Age 20 years old or older
  • 6) Performance Status:0-1(ECOG)
  • 7) No past history of surgery or chemotherapy for pancreatic cancer
  • 8) No past history of radiation therapy to the abdomen
  • 9) Sufficient organ functions

排除标准

  • 1) Synchronous multiple cancers
  • 2) Infectious disease to be treated
  • 3) Past history of systemic steroid therapy (>10 mg/body of prednisolone) within 14 days
  • 4) Active peptic ulcer
  • 5) Interstitial pneumonia, pulmonary fibrosis, or inflammatory lung disease confirmed by medical history or imaging test
  • 6) Pleural, pericardial, or abdominal effusion

研究者

发起方
-

相似试验